Moolec Science (MLECW) Income from Non-Controlling Interests (2022 - 2024)
Moolec Science (MLECW) posted Income from Non-Controlling Interests of -$2.3 million for Q4 2024, down 61.49% sequentially from -$1.4 million in Q3 2024, and up 14.71% YoY from -$2.0 million in Q1 2024.
Moolec Science (MLECW) Income from Non-Controlling Interests (2022 - 2024) Analysis & Trends
Moolec Science has reported Income from Non-Controlling Interests for 3 years, with the latest figure at -$2.3 million in Q4 2024.
- Quarterly Income from Non-Controlling Interests rose 14.71% year-over-year to -$2.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.1 million (down 95.24% YoY) and the FY2024 annual result came in at $107597.0, up 494.06% from the prior year.
- Income from Non-Controlling Interests eased to -$2.3 million in Q4 2024 per MLECW's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $49.1 million in Q2 2023 and troughed at -$48.0 million in Q4 2022.
- A 3-year average of $41430.3 and a median of -$358578.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests slumped 324.79% in 2023, then soared 336.35% in 2024.
- Over 3 years, Income from Non-Controlling Interests stood at -$48.0 million in 2022, then soared by 94.44% to -$2.7 million in 2023, then grew by 14.71% to -$2.3 million in 2024.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$2.3 million, -$1.4 million, and $5.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.27 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | 4.95 Mn |
| Mar 31, 2024 | 847,485.00 |
| Dec 31, 2023 | -2.67 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | 49.06 Mn |
| Mar 31, 2023 | -358,578.00 |
| Dec 31, 2022 | -47.96 Mn |
| Sep 30, 2022 | 721,426.00 |
| Mar 31, 2022 | 1.17 Mn |